Takeda received regulatory acceptance for zasocitinib in moderate-to-severe psoriasis
Takeda said that on September 14, 2026, the FDA and the European Medicines Agency (EMA) accepted applications for zasocitinib (TAK‑279) to treat moderate-to-severe plaque psoriasis, opening the way to further regulatory review.
Key points
- The FDA accepted a new New Drug Application (NDA) under a priority review program, and the EMA accepted a new marketing authorization application (MAA), both for zasocitinib in adult moderate-to-severe plaque psoriasis.
- The drug is intended for patients diagnosed with moderate-to-severe plaque psoriasis who need new systemic therapies.
- Zasocitinib is an investigational, highly selective TYK2 inhibitor that in laboratory studies showed more than a million‑fold greater selectivity for TYK2 compared with other JAK enzymes.
Regulators approved the drug applications.
The FDA accepted a new New Drug Application (NDA) under a priority review program, and the EMA accepted a new marketing authorization application (MAA), both for zasocitinib in adult moderate-to-severe plaque psoriasis.
Who will benefit
The drug is intended for patients diagnosed with moderate-to-severe plaque psoriasis who need new systemic therapies.
Existing evidence base
Zasocitinib is an investigational, highly selective TYK2 inhibitor that in laboratory studies showed more than a million‑fold greater selectivity for TYK2 compared with other JAK enzymes. The company is already conducting Phase 3 trials in psoriatic arthritis and Phase 2 trials in patients with Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa.
Next steps
The FDA and EMA will now review the submitted applications; the outcomes will determine whether zasocitinib receives approval in the United States and Europe. Simultaneously, Takeda continues to assess the drug’s safety and efficacy in ongoing phase studies, which will inform possible label expansions.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Takeda Pharmaceutical
A notification in your browser or on your phone when we publish about Takeda Pharmaceutical. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
